Clinical evidence · Primary data

The studies behind Floradyle®.

6 clinical and biochemical studies — full data tables, designs and outcomes from the Floradyle® scientific compendium. Independent research includes work at the Technical University of Munich (Prof. Erich F. Elstner) and integrative oncology centres.

+122%

ATP increase

82.5%

IBS improved

500+

Phenolic compounds

90.5%

Tolerability good/v.good

Cellular Energy

Chronic fatigue cohort — cellular ATP & vitality

Population

n = 31 adults with chronic energy deficit (CFS-spectrum)

Duration

6 months

Design

Open-label, prospective; granulocyte ATP measured by chemiluminescence; self-report on energy, focus and fitness

Intervention

20 ml Floradyle® Essence daily (10 ml AM + 10 ml PM)

Primary outcome

Granulocyte ATP concentration (µM)

Result

+122% mean increase in cellular ATP; +55% energy & motivation, +58% concentration, +60% physical fitness

Data table

Marker	Baseline	After 6 months	Change
Granulocyte ATP (µM)	0.68	1.51	+122%
Energy & motivation (self-report)	—	—	+55%
Concentration (self-report)	—	—	+58%
Physical fitness (self-report)	—	—	+60%

ATP is the universal energy currency every cell uses. Below 40% of normal ATP, cells begin to fail.

Gastrointestinal

IBS prospective study — symptom resolution

Population

n = 52 patients with diagnosed Irritable Bowel Syndrome

Duration

8 weeks

Design

Prospective, observational; validated IBS symptom diary; tolerability rating

Intervention

10 ml Floradyle® twice daily before meals

Primary outcome

Symptom severity (diarrhoea, bloating, cramps) and overall improvement

Result

82.5% of patients improved overall; tolerability rated good or very good by 90.5%

Data table

Symptom	Reduction at 8 weeks
Diarrhoea severity	−78%
Bloating	−73%
Abdominal cramps	−73%
Patients improved overall	82.5%
Tolerability good/very good	90.5%

Diarrhoea-type IBS responded most strongly. L(+) lactic acid and postbiotic peptides rebalance gut flora.

Cardio-Metabolic

Type-2 diabetes & metabolic syndrome — uric acid & liver function

Population

n = 13 patients with type-2 diabetes and/or metabolic syndrome (10 obese)

Duration

6 months + 3-month follow-up

Design

Open-label observational; serum biochemistry pre / 3 mo / 6 mo / follow-up

Intervention

10 ml Floradyle® Essence Special Diet, morning and evening

Primary outcome

Uric acid, γ-GT, ALT, creatinine and electrolyte balance

Result

Mean uric acid 5.7 → 4.8 → 5.1 mg/dl. γ-GT and ALT significantly reduced. Excretory kidney function improved.

Data table

Marker	Baseline	3 months	6 months	Follow-up (+3 mo)
Uric acid (mg/dl, mean)	5.7	4.8	5.1	rose again in 9 patients who stopped
γ-GT (liver enzyme)	elevated	—	significantly lower	—
ALT (liver enzyme)	elevated	—	significantly lower	—
Creatinine (kidney)	elevated	—	improved	—
Electrolytes	imbalanced	—	normalised	—

Source: open-label CAM-practice cohort. Improvements regressed after discontinuation, indicating an ongoing regulatory effect.

Biochemistry

TU München — antioxidant capacity in oxidative-stress models

Population

Five biochemical reaction systems

Duration

—

Design

In vitro biochemistry, Prof. Erich F. Elstner's group, Centre of Life and Food Sciences (Freising-Weihenstephan)

Intervention

Floradyle® Essence vs. gallic acid and salicylic acid as reference

Primary outcome

IC50 (concentration causing 50% inhibition) of reactive oxygen species in each model

Result

Floradyle® consistently quenched ROS across all five models; phenol content measured at 3 mM (Folin-Ciocalteu) — 164 µg/ml total phenols

Data table

Model system	What it simulates	Floradyle® action
Xanthine / xanthine oxidase	Inflammatory ROS production	Strong inhibition vs. KMB indicator
Fenton reaction	Hydroxyl radicals (•OH) — most damaging ROS	Effective scavenging
NADH / diaphorase	Redox stress in mitochondria	Significant ROS reduction
Peroxynitrite (ONOO−)	Nitric-oxide-driven tissue damage	Quenched
Hypochlorous acid (HOCl)	Neutrophil oxidative burst	Quenched

500+ different phenolic compounds identified in Floradyle®, mostly antioxidants. Lactobacillus cell-wall material additionally binds toxins.

Oncology supportive care

Chemo- / radiation-induced oral mucositis

Population

Two studies — n = 9 (ENT cancers, chemo + radio) and n = 11 (chemo-induced mucositis, Dr P. Holzhauer, Bad Trissl Hospital)

Duration

Treatment course (3–4 weeks)

Design

Topical mouth spray + oral supplementation alongside oncological treatment

Intervention

Mouth spray (1:1 dilution) 6–8× daily + 1 dessertspoon Floradyle® twice daily

Primary outcome

WHO mucositis grade and severity score (0–24)

Result

Severity scores reduced from severe (>17) to mild within 3–4 weeks; one patient remained completely symptom-free during second cycle

Data table

WHO Grade	Definition	Outcome with Floradyle®
0	None	1 patient
1	Pain in mouth, erythema	6 patients (mild local toxicity only)
2	Erythema, ulceration — solids tolerated	2 patients (still ate normally)
3–4	Severe ulceration, only liquids / no intake	0 patients

Mean baseline mucositis score 12.73 dropped substantially after 3–4 weeks of Floradyle® mouthwash protocol.

Allergy

Hay fever — combined oral + topical case series

Population

Documented case + practice cohort with seasonal allergic rhinitis

Duration

3 days to symptom resolution

Design

Open-label combined protocol

Intervention

20 ml oral daily + nasal spray (1:3) several times/day + 1:2 diluted eye compresses

Primary outcome

Sneezing, watering eyes, facial swelling, mucosal redness

Result

Sneezing and watering eyes considerably improved; facial swelling and redness resolved within 3 days

Full scientific compendium

Methods, references, biochemical pathways, indication-by-indication evidence and practitioner protocols — all in one downloadable PDF.

Download compendium

Floradyle® is a food supplement, not a medicine. Information here summarises clinical observation and primary research and is not a substitute for medical advice.